Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ?50%: KEYNOTE-598 3-year follow-up

Basit Öğe Kaydı
dc.authoridBoyer, Michael/0000-0002-0452-2987
dc.authorwosidBoyer, Michael/GZG-2105-2022
dc.contributor.authorAbreu, D. Rodriguez
dc.contributor.authorReck, M.
dc.contributor.authorSendur, N.
dc.contributor.authorPark, K.
dc.contributor.authorLee, D. H.
dc.contributor.authorCicin, I.
dc.contributor.authorYumuk, P. F.
dc.date.accessioned2024-06-12T11:20:22Z
dc.date.available2024-06-12T11:20:22Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.descriptionEuropean Lung Cancer Congress (ELCC) -- MAR 30-APR 02, 2022 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.description.sponsorshipMSD Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USAen_US
dc.description.sponsorshipMSD Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.en_US
dc.identifier.doi10.1016/j.annonc.2022.02.015
dc.identifier.endpageS31en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS30en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.02.015
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25577
dc.identifier.volume33en_US
dc.identifier.wosWOS:000778453100007en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titlePembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ?50%: KEYNOTE-598 3-year follow-upen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu